MARKET

ZYME

ZYME

Zymeworks
NYSE

Real-time Quotes | Nasdaq Last Sale

30.24
-0.06
-0.18%
Opening 13:17 08/13 EDT
OPEN
30.09
PREV CLOSE
30.29
HIGH
31.04
LOW
29.81
VOLUME
160.16K
TURNOVER
--
52 WEEK HIGH
52.75
52 WEEK LOW
20.33
MARKET CAP
1.38B
P/E (TTM)
-8.0357
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZYME stock price target is 54.92 with a high estimate of 70.00 and a low estimate of 42.00.

EPS

ZYME News

More
Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season?
Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/06 12:43
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 26.74% and 44.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 00:55
Zymeworks Reports 2020 Second Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020.
Business Wire · 08/05 20:15
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/31 16:30
Did Hedge Funds Make The Right Call On Zymeworks Inc. (ZYME) ?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 07/12 14:17
Zymeworks Corporate Update Webcast and Conference Call Summary
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.
Business Wire · 07/08 21:30
Merck inks new deal with Zymeworks for up to three antibodies
Seeking Alpha - Article · 07/08 20:26
Zymeworks Announces New Multispecific Antibody Collaboration with Merck; Zymeworks Eligible To Receive Up To $411M In Option Exercise Fees And Clinical Development And Regulatory Approval Milestone Payments And Up To $480M In Commercial Milestone Payments
Benzinga · 07/08 20:16

Industry

Biotechnology & Medical Research
+0.76%
Pharmaceuticals & Medical Research
-1.17%

Hot Stocks

Symbol
Price
%Change

About ZYME

Zymeworks Inc. a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It also developed ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.
More

Webull offers kinds of Zymeworks Inc stock information, including NYSE:ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.